CClinicalTrials.gg
SuspendedNCT06627842OASISUpdated Jun 2, 2026

OsteoArticular Sepsis in Intensive Care unitS

An observational study in Osteoarticular Infection, Intensive Care Patients and Prosthetic Joint Infection, sponsored by Assistance Publique - Hôpitaux de Paris. Suspended at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Why this study was suspended
Temporary suspended. Wait for IRB approval (inclusion duration modified)
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

This is an ambispective observational study of patients admitted to intensive care with a diagnosis of joint prosthesis infection (mainly knee and hip prostheses). The main objective of the study is to describe the profile, care trajectories during the stay (before or after surgery) and prognosis of patients admitted to critical care with such an infection. We also aim to compare prognosis between different groups of patients sharing the same profile and care trajectory, and to assess independent risk factors associated with 2-year mortality among the study population. Finally, we will describe the microbiological and resistance profile of severe osteoarticular device infections requiring critical care admission in France.

This is a descriptive and analytical observational study open to all French public and private hospitals.

Patient data will be retrieved prospectively from patient source files. Only 2-year data (vital status, functional data) will be collected specifically for the study, by telephone contact with the patient or his or her support person.

02

Conditions studied

  • Osteoarticular Infection
  • Intensive Care Patients
  • Prosthetic Joint Infection

Browse trials for

Keywords

  • Osteoarticular sepsis
  • sepsis
  • osteoarticular prothetis
  • intensive care
  • critical care
  • prosthetic joint infection
03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's planned enrollment of 150 is close to the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critical care patients (intensive care and continuing care), admitted between 2018 and 2022 with a principal or associated diagnosis of prosthetic joint infection.

Inclusion criteria

  • Patient at least 18 years old.
  • Hospitalization in critical care (intensive care unit or continuing care unit) between 2018 and 2022 of at least 48 hours, with prosthetic joint infection (hip, knee or shoulder prosthesis infection) as the main or associated diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Infection on osteosynthesis material
  • Infection on spinal equipment
  • Patient with several infected prostheses
  • Recurrence of infection on prosthesis with the same microorganism
  • Patient opposing data collection
  • Patient under legal protection.
  • Pregnant or breast-feeding patient.
  • Patient deprived of liberty.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Global cohort

    All patients admitted to intensive care during the study period

06

What researchers measure

Primary outcomes

  1. The profile, trajectories of care during the stay (before or after surgery) and the prognosis of patients admitted to intensive care for joint prosthesis infection over a 2-year period after admission to intensive care.

    Time frame: 2 years

Secondary outcomes

  1. Composite endpoint reflecting poor clinical outcome

    * Mortality, measured in critical care, at 30 days, 1 year and 2 years * Therapeutic failure at 2 years, defined as mechanical or septic failure. * Functional failure at 2 years, defined as failure to resume walking and usual activities, to return home, or to regain autonomy.

    Time frame: 2 years

  2. Mortality at 2 years

    Time frame: 2 years

  3. Description of pathogens found in intraoperative samples, and their resistance spectrum

    Time frame: 2 years

07

Study locations

1 site
  • Hôpital Lariboisière
    Paris, France 75010, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06627842
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Mar 31, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Carine PARE
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion